Ascendis Pharma Reports Results of TransCon PTH in P-III (PaTHway) Trial for the Treatment of Hypoparathyroidism
Shots:
- The P-III (PaTHway) trial evaluates TransCon PTH vs PBO in a ratio (3:1) in 82 adults patients with chronic HP
- The therapy showed an improvement on the primary composite EPs & 2EPs, 78.7% vs 4.8% achieved serum calcium levels in the normal range & independence from therapeutic levels of conventional therapy, reduction in patient-reported disease impact along with physical & cognitive symptoms, was well tolerated with no discontinuations related to study drug, TEAEs (82% vs 100%). The top-line results are expected in Q3’22
- The company plans to submit an NDA to the US FDA for TransCon PTH in Q3’22 & MAA to EMA in Q4’22 & is also planning to initiate a clinical trial in pediatric HP in Q4’22
Ref: Globe Newswire | Image: Ascendis Pharma
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
